Balverde, Judy Ann D.
HRN: 14-39-40 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/21/2025
CO-AMOXICLAV 625MG (TAB)
12/21/2025
12/28/2025
ORAL
500mg
BID
S/P NSD With Repair; PROM
Checking Initial Appropriateness
Indication: Prophylaxis Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines